Methicillin Resistant Staphylococcus aureus (MRSA): A Comprehensive Review of Pathogenesis, Resistance Mechanisms, Clinical Manifestations, and Therapeutic Strategies

Methicillin resistant Staphylococcus aureus (MRSA) is a non motile bacterium that frequently colonizes the nose and skin without causing disease. When it enters the body through breaches like cuts or invasive procedures, it can disseminate, causing a wide range of infections, from skin and soft tissue infections (painful nodules, abscesses) to life threatening conditions like pneumonia and endocarditis. Both healthcare associated (HA-MRSA) and community associated (CA-MRSA) strains contribute significantly to a rising global disease burden. Diagnosis of MRSA is achieved through culture and sensitivity testing, Gram staining, quantitative PCR, and antibiotic susceptibility assays. The organism employs multiple resistance mechanisms, including biofilm formation, efflux pumps, and modification of antibiotic targets, a challenge increasingly evident during recent global health crises. The clinical presentation is often characterized by painful erythematous nodules and purulent lesions, frequently accompanied by fever. Severe cases can rapidly progress to necrotizing soft tissue disease. Standard first line therapy relies on agents like vancomycin and daptomycin, with alternatives including linezolid and ceftaroline. However, resistance and drug toxicity complicate management. To combat these issues, novel therapeutic strategies are being developed, including newer antibiotics (e.g., tigecycline, tedizolid), optimized delivery systems (e.g., inhalable vancomycin nanoparticles), and bacteriophage therapy. Core prevention measures meticulous hand hygiene, environmental cleaning, and targeted decolonization remain essential to limit transmission. The increasing prevalence and expanding resistance mechanisms of MRSA underscore the critical need for continued research and robust infection control in the 21st century.